Matching articles for "cholangiocarcinoma"
In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)
The oral kinase inhibitor pemigatinib ( Pemazyre – Incyte) has been approved by the FDA for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor…
Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e71-2 doi:10.58347/tml.2023.1674g
The oral kinase inhibitor pemigatinib ( Pemazyre – Incyte) has been approved by the FDA for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. It is the first targeted therapy to be approved in the US for this indication. The drug received accelerated approval from the FDA in 2020 for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements.
Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic…
Med Lett Drugs Ther. 2020 Dec 28; 62(1614):e208-9
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Pemigatinib is the first drug to be approved in the US for this indication.
